Furthermore, the combination of the Mucin-1 (MUC1)-mRNA DC vaccine with CTLA-4 blockade outperformed either the DC vaccine or CTLA-4 blockade alone in patients with triple-negative breast cancer (TNBC) [52] (Figure 1). This evidence concerns the gene MUC1 and triple-negative breast carcinoma.